Joachim Burman
Adjunct senior lecturer at Institutionen för medicinska vetenskaper; Experimentell neurologi
- E-mail:
- joachim.burman@neuro.uu.se
- Visiting address:
- BMC, Husargatan 3
75123 UPPSALA - Postal address:
- Box 593
75124 UPPSALA
More information is available to staff who log in.
Short presentation
In my research, I am investigating biological and clinical effects of hematopoietic stem cell transplantation as treatment for multiple sclerosis in order to understand which patients benefit most from HSCT; describe efficacy and side effects of HSCT; and elucidate why HSCT is effective.
Publications
Recent publications
- Innovative cellular therapies for autoimmune diseases (2024)
- Evoked potentials after autologous hematopoietic stem cell transplantation for multiple sclerosis (2024)
- Cerebrospinal fluid mtDNA concentrations are increased in multiple sclerosis and were normalized after intervention with autologous hematopoietic stem cell transplantation (2024)
- Experiences of being treated with autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: A qualitative interview study (2024)
- Levels of inflammatory cytokines MCP-1, CCL4, and PD-L1 in CSF differentiate idiopathic normal pressure hydrocephalus from neurodegenerative diseases (2023)
All publications
Articles
- Innovative cellular therapies for autoimmune diseases (2024)
- Evoked potentials after autologous hematopoietic stem cell transplantation for multiple sclerosis (2024)
- Cerebrospinal fluid mtDNA concentrations are increased in multiple sclerosis and were normalized after intervention with autologous hematopoietic stem cell transplantation (2024)
- Experiences of being treated with autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: A qualitative interview study (2024)
- Levels of inflammatory cytokines MCP-1, CCL4, and PD-L1 in CSF differentiate idiopathic normal pressure hydrocephalus from neurodegenerative diseases (2023)
- Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis (2023)
- Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort (2023)
- Disease phenotype prediction in multiple sclerosis (2023)
- Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis (2023)
- Antibody-Positive Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome (2023)
- Antibodies from serum and CSF of multiple sclerosis patients bind to oligodendroglial and neuronal cell-lines (2023)
- Plasma neurofilament light chain is elevated after transcatheter aortic valve implantation (2023)
- Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients (2023)
- Image-derived input functions from dynamic O-15-water PET scans using penalised reconstruction (2023)
- Anti-Müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis (2023)
- Evaluation of polarity switching for untargeted lipidomics using liquid chromatography coupled to high resolution mass spectrometry (2022)
- Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT (2022)
- Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology (2022)
- COVID-19 clinical outcomes and DMT of MS patients and population-based controls (2022)
- Temporal trends of epilepsy in multiple sclerosis (2022)
- Serum Neurofilament Light Chain in Patients With Atrial Fibrillation (2022)
- Distribution of five clinically important neuroglial proteins in the human brain. (2022)
- Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden (2022)
- Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis (2022)
- Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab (2022)
- Biomarkers of demyelination and axonal damage are decreased after autologous hematopoietic stem cell transplantation for multiple sclerosis (2022)
- Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases (2021)
- Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis (2021)
- Intrathecal treatment trial of rituximab in progressive MS (2021)
- Delaying the inevitable (2021)
- New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis (2021)
- Metabolomics of Cerebrospinal Fluid from Healthy Subjects Reveal Metabolites Associated with Ageing (2021)
- Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis (2021)
- Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19 (2021)
- Cerebral blood flow measurements with 15O-water PET using a non-invasive machine-learning-derived arterial input function (2021)
- Retention of antiseizure medications for epilepsy in multiple sclerosis (2021)
- Neuronal and glial CSF biomarkers in multiple sclerosis (2021)
- Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease (2021)
- Metabolic drift in the aging nervous system is reflected in human cerebrospinal fluid (2021)
- Urokinase, CX3CL1, CCL2, TRAIL and IL-18 induced by interferon-β treatment (2021)
- Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis (2021)
- Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients (2020)
- Location matters (2020)
- Targeted metabolomics of CSF in healthy individuals and patients with secondary progressive multiple sclerosis using high-resolution mass spectrometry (2020)
- Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS (2020)
- Intrathecal immunoglobulins and neurofilament light after autologous haematopoietic stem cell transplantation for multiple sclerosis (2020)
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies (2020)
- Prognostic impact of epilepsy in multiple sclerosis (2020)
- Rehabilitation Before and After Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for Patients With Multiple Sclerosis (MS) (2020)
- Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases (2020)
- Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison (2020)
- Profound but Transient Changes in the Inflammatory Milieu of the Blood During Autologous Hematopoietic Stem Cell Transplantation (2020)
- Validation of the Swedish Multiple Sclerosis Register (2019)
- Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology (2019)
- Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis (2019)
- Interoperable and scalable data analysis with microservices (2019)
- Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease (2019)
- Alterations in the tyrosine and phenylalanine pathways revealed by biochemical profiling in cerebrospinal fluid of Huntington's disease subjects (2019)
- Biochemical Differences in Cerebrospinal Fluid between Secondary Progressive and Relapsing-Remitting Multiple Sclerosis (2019)
- Container-based bioinformatics with Pachyderm (2019)
- Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation (2019)
- Intrathecal treatment trial of rituximab in progressive MS An open-label phase 1b study (2018)
- Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden (2018)
- Autologous haematopoietic stem cell transplantation for neurological diseases (2018)
- Non-myeloablative hematopoietic stem cell transplantation (HSCT) is superior to disease modifying drug (DMD) treatment in highly active Relapsing Remitting Multiple Sclerosis (RRMS) (2018)
- Treatment of epilepsy in multiple sclerosis (2018)
- The use of autologous haematopoietic stem cell transplantation as a first line disease modifying therapy in patients with 'aggressive' multiple sclerosis. (2018)
- A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5) (2018)
- A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of teriflunomid (IMSE 4) (2018)
- A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of fingolimod (IMSE 2) (2018)
- A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3) (2018)
- Integration of magnetic resonance imaging and protein and metabolite CSF measurements to enable early diagnosis of secondary progressive multiple sclerosis. (2018)
- A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of natalizumab (IMSE 1) (2018)
- Real-world longitudinal data of peginterferon beta-1a from a Swedish national post-marketing surveillance study (IMSE 6) - efficacy and safety profile (2018)
- Risk of epilepsy after a single seizure in multiple sclerosis (2018)
- Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease (2018)
- Baseline characteristics from the COMBAT-MS study (2017)
- Autologous hematopoietic stem cell transplantation for MS (2017)
- Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis (2017)
- Epilepsy in multiple sclerosis (2017)
- Blogs cannot separate wheat from chaff (2017)
- Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients (2017)
- A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5) (2017)
- A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of teriflunomid (IMSE 4) (2017)
- Inflammatory immune response after autologous transplantation in neurologic diseases (2017)
- A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of natalizumab (IMSE 1) (2017)
- The diagnosis of OCB-negative MS-patients - an inventory of the Swedish MS register in Uppsala, Sweden (2017)
- A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of fingolimod (IMSE 2) (2017)
- A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3) (2017)
- Quantification of γδ T cells and HLA-DR+ NK cells does not predict emergence of new contrast enhancing lesions in MS patients suspending natalizumab treatment (2017)
- Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases (2017)
- Corpus callosum atrophy in MS is halted by autologous haematopoietic stem cell transplantation (2017)
- Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis (2017)
- Rituximab in multiple sclerosis; data from the swedish MS registry. (2016)
- Adverse events of rituximab in a Swedish MS population sample. (2016)
- YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. (2016)
- Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis. (2016)
- Real world experience of fingolimod after switching multiple sclerosis (MS) therapy; focus on natalizumab naive and experienced persons with MS, respectively (2016)
- A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5) (2016)
- A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of natalizumab (IMSE 1) (2016)
- Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis (2015)
- Severe relapses and rebound activity after natalizumab discontinuation in MS patients with more than five years of treatment with stable disease course (2015)
- A Swedish nationwide pharmaco-epidemiological and genetic study (IMSE) of the long-term safety and efficacy of dimethyl fumarate (2015)
- Autologous hematopoietic stem cell transplantation in neuromyelitis optica (2015)
- A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and efficacy of natalizumab (2015)
- The IMSE 2 study (2015)
- A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia (2015)
- Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases (2015)
- Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis (2014)
- Tim-3 and PD-1 (2014)
- The cerebrospinal fluid cytokine signature of multiple sclerosis (2014)
- Assessing tissue damage in multiple sclerosis (2014)
- Normal outcome of pregnancy with ongoing treatment with natalizumab (2014)
- Intranasal Delivery of CNS-Retargeted Human Mesenchymal Stromal Cells Prolongs Treatment Efficacy of Experimental Autoimmune Encephalomyelitis (2014)
- A Swedish nationwide pharmaco-epidemiological and genetic study (IMSE) of the long-term safety and efficacy of natalizumab (2014)
- T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis (2013)
- Autologous hematopoietic stem cell transplantation for multiple sclerosis (2012)
- CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery (2012)
- Svenska neurologföreningen (2012)
- Bilateral and recurrent optic neuritis in multiple sclerosis (2011)
- T regulatory cells lacking CD25 are increased in MS during relapse (2010)
- Human Mesenchymal stromal cells expressing a CNS-targeting receptor can be administrated intra nasally and cure expersimental autoimmune enchphlomyelitis
- Engineered T regulatory cells target CNS and suppress active EAE upon intra nasal delivery
- A biochemical signature of progressive multiple sclerosis
- Biological markers for CNS damage in a patient cohort with suspected autoimmune psychiatric disease
- Cerebral blood flow in multiple sclerosis: an 15O-water PET study
Books
Chapters
